A 48-year-old homeless man with alcohol dependency presents with a 6-week history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper zone cavitation. Three sputum samples are sent for acid-fast bacilli. What is the minimum number of positive sputum smears required to classify this patient as having smear-positive pulmonary tuberculosis for public health notification purposes?
Q142
A 42-year-old man with HIV infection (CD4 count 65 cells/mm³) presents with a 3-week history of headache, fever, and confusion. CT head shows basal meningeal enhancement. Lumbar puncture reveals opening pressure 32 cmH2O, white cells 45 cells/mm³ (lymphocytes), protein 1.2 g/L, glucose 1.8 mmol/L (plasma 5.2 mmol/L). India ink stain is positive. What is the most appropriate initial management strategy?
Q143
A 3-year-old girl presents with a 24-hour history of fever, irritability, and refusing to walk. On examination, she is drowsy with a temperature of 39.5°C and has positive Kernig's sign. Lumbar puncture shows: opening pressure 25 cmH2O, white cell count 850 cells/mm³ (85% lymphocytes), protein 0.8 g/L, glucose 2.8 mmol/L (plasma glucose 5.5 mmol/L). What is the most appropriate interpretation of these cerebrospinal fluid findings?
Q144
A 58-year-old man with previously treated pulmonary tuberculosis develops recurrent disease. Culture and sensitivity testing reveals resistance to rifampicin and isoniazid, but sensitivity to ethambutol, pyrazinamide, and fluoroquinolones. What is the minimum recommended duration of treatment for his multidrug-resistant tuberculosis?
Q145
A 25-year-old man presents to the emergency department with a 10-hour history of fever, severe headache, and vomiting. On examination, he has a temperature of 39.2°C, heart rate 118/min, blood pressure 95/60 mmHg, and a non-blanching purpuric rash on his lower limbs. Which organism is most likely responsible for his clinical presentation?
Q146
A 34-year-old woman with pulmonary tuberculosis is currently on rifampicin, isoniazid, pyrazinamide, and ethambutol. She develops painful, red eyes with blurred vision. Ophthalmology examination reveals bilateral optic neuritis. Which medication is most likely responsible for this complication?
Q147
A 36-year-old man from Bangladesh completes 6 months of treatment for drug-sensitive pulmonary tuberculosis with rifampicin, isoniazid, pyrazinamide, and ethambutol (2 months) followed by rifampicin and isoniazid (4 months). He is clinically well. End-of-treatment chest X-ray shows residual upper lobe fibrosis but no active disease. Sputum samples are smear and culture negative. He asks about risk of recurrence. Which factor most significantly increases his risk of TB relapse after treatment completion?
Q148
A 51-year-old man from Zimbabwe with newly diagnosed HIV (CD4 count 45 cells/mm³, viral load 450,000 copies/mL) presents with a 4-week history of headache, confusion, and fever. Cryptococcal antigen (CrAg) in serum and CSF is positive. Opening pressure on LP is 38 cmH2O. He is started on liposomal amphotericin B and flucytosine. When is the most appropriate time to initiate antiretroviral therapy?
Q149
A 29-year-old woman presents with headache, fever, and photophobia. LP shows: opening pressure 24 cmH2O, CSF clear with 450 white cells/mm³ (85% lymphocytes), protein 0.8 g/L, glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L). She was treated with IV aciclovir for suspected HSV encephalitis. CSF PCR is negative for HSV, VZV, and enteroviruses. Blood and CSF cultures are sterile at 48 hours. She improves clinically. What is the most likely diagnosis?
Q150
A 44-year-old woman with rheumatoid arthritis on methotrexate and newly commenced tocilizumab (IL-6 inhibitor) undergoes screening for latent tuberculosis. Mantoux test shows 18 mm induration at 48 hours. Chest X-ray shows calcified granuloma in the right upper zone but no active disease. Interferon-gamma release assay is positive. She has no symptoms of active TB. What is the most appropriate management?
Serious & Notifiable Infections UK Medical PG Practice Questions and MCQs
Question 141: A 48-year-old homeless man with alcohol dependency presents with a 6-week history of cough, weight loss, and night sweats. Chest X-ray shows bilateral upper zone cavitation. Three sputum samples are sent for acid-fast bacilli. What is the minimum number of positive sputum smears required to classify this patient as having smear-positive pulmonary tuberculosis for public health notification purposes?
A. All three sputum samples must be positive
B. At least two out of three sputum samples must be positive (Correct Answer)
C. At least one out of three sputum samples must be positive
D. Only one sample is needed if it is strongly positive (3+ or 4+)
E. Positive smear is not required if GeneXpert MTB/RIF is positive
Explanation: ***At least two out of three sputum samples must be positive***
- According to **WHO** and public health guidelines, a patient is classified as **smear-positive pulmonary TB** if at least **two** sputum samples are positive for **Acid-Fast Bacilli (AFB)** on microscopy.
- This classification is critical for assessing **infectivity**, prioritizing **contact tracing**, and determining the urgency of **respiratory isolation**.
*All three sputum samples must be positive*
- Requiring all three samples to be positive would be insensitive for diagnosis and delay **public health notification**.
- Two positive smears are sufficient to confirm high bacterial load and define a **notifiable case** of smear-positive TB.
*At least one out of three sputum samples must be positive*
- While a single positive smear is clinically significant and warrants treatment, traditional **public health classification** typically requires two for the "smear-positive" label.
- In specific regions, a single positive smear may suffice if there is clear **radiological evidence** (like upper zone cavitation), but it is not the standard three-sample rule definition.
*Only one sample is needed if it is strongly positive (3+ or 4+)*
- The **grading of the smear** (e.g., 3+ or 4+) indicates a high bacterial burden but does not legally change the requirement from two samples to one for official classification.
- Consistency across **multiple samples** is used to reduce the risk of laboratory error or environmental contaminant misinterpretation.
*Positive smear is not required if GeneXpert MTB/RIF is positive*
- **GeneXpert MTB/RIF** is a molecular test and classifies a patient as "**bacteriologically confirmed**," not necessarily "**smear-positive**."
- Smear status is specifically monitored via **microscopy** because it is a better predictor of how **contagious** the patient is compared to nucleic acid amplification tests.
Question 142: A 42-year-old man with HIV infection (CD4 count 65 cells/mm³) presents with a 3-week history of headache, fever, and confusion. CT head shows basal meningeal enhancement. Lumbar puncture reveals opening pressure 32 cmH2O, white cells 45 cells/mm³ (lymphocytes), protein 1.2 g/L, glucose 1.8 mmol/L (plasma 5.2 mmol/L). India ink stain is positive. What is the most appropriate initial management strategy?
A. Intravenous amphotericin B and oral flucytosine for 2 weeks, followed by fluconazole consolidation (Correct Answer)
B. Oral fluconazole 400 mg daily for 6 weeks
C. Intravenous ceftriaxone and vancomycin
D. Standard four-drug anti-tuberculosis therapy
E. Intravenous aciclovir and empirical antibacterial therapy
Explanation: ***Intravenous amphotericin B and oral flucytosine for 2 weeks, followed by fluconazole consolidation***
- The patient's **HIV infection** with a very **low CD4 count (65 cells/mm³)**, characteristic CSF findings, and a **positive India ink stain** unequivocally diagnose **Cryptococcal meningitis**.
- The recommended **induction therapy** for severe Cryptococcal meningitis involves a combination of **liposomal amphotericin B** and **flucytosine** for at least 2 weeks, followed by **fluconazole consolidation** and maintenance, as this regimen significantly reduces mortality and fungal load.
*Oral fluconazole 400 mg daily for 6 weeks*
- **Fluconazole monotherapy** is insufficient and associated with higher treatment failure rates for the **induction phase** of severe Cryptococcal meningitis, especially in immunocompromised patients.
- Fluconazole is primarily used for the **consolidation and maintenance phases** after the intensive initial induction therapy, not as primary induction.
*Intravenous ceftriaxone and vancomycin*
- This regimen targets **acute bacterial meningitis**, which typically presents with a more rapid onset and a predominance of neutrophils in the CSF.
- These antibiotics have **no antifungal activity** and would be entirely ineffective against *Cryptococcus neoformans*, which was confirmed by the India ink stain.
*Standard four-drug anti-tuberculosis therapy*
- While **Tuberculous meningitis** can mimic Cryptococcal meningitis with similar CSF findings and **basal meningeal enhancement** in immunocompromised patients.
- The **positive India ink stain** specifically identifies *Cryptococcus*, making anti-tuberculosis therapy an inappropriate initial management strategy in this case.
*Intravenous aciclovir and empirical antibacterial therapy*
- **Aciclovir** is an antiviral agent used for conditions like **herpes simplex encephalitis**, which typically presents with different clinical and radiological features, often with focal neurological signs.
- This treatment strategy lacks the essential **antifungal coverage** required to effectively treat **Cryptococcal meningitis**, a fungal infection confirmed by the laboratory results.
Question 143: A 3-year-old girl presents with a 24-hour history of fever, irritability, and refusing to walk. On examination, she is drowsy with a temperature of 39.5°C and has positive Kernig's sign. Lumbar puncture shows: opening pressure 25 cmH2O, white cell count 850 cells/mm³ (85% lymphocytes), protein 0.8 g/L, glucose 2.8 mmol/L (plasma glucose 5.5 mmol/L). What is the most appropriate interpretation of these cerebrospinal fluid findings?
A. Normal cerebrospinal fluid
B. Bacterial meningitis
C. Viral meningitis (Correct Answer)
D. Tuberculous meningitis
E. Partially treated bacterial meningitis
Explanation: ***Viral meningitis***
- The CSF findings of **lymphocytic pleocytosis** (85% lymphocytes), moderately elevated protein (0.8 g/L), and a **normal to mildly reduced CSF glucose ratio** (0.51) are highly characteristic of viral meningitis.
- The elevated opening pressure (25 cmH2O) and fever, irritability, and positive Kernig's sign support an inflammatory meningeal process, which is consistent with a viral etiology.
*Normal cerebrospinal fluid*
- Normal CSF would show a **white cell count** of <5 cells/mm³, a protein level <0.45 g/L, and an opening pressure <20 cmH2O.
- This patient's CSF has a significantly elevated white cell count (850 cells/mm³), elevated protein, and elevated opening pressure, clearly indicating **pathology**.
*Bacterial meningitis*
- Bacterial meningitis typically presents with a **neutrophilic pleocytosis** (predominance of neutrophils) and a **markedly low CSF glucose** (ratio <0.4 or absolute value <2.2 mmol/L).
- The white cell count is usually much higher (often >1000 cells/mm³) with more significantly elevated protein (>1.0 g/L), which differs from these findings.
*Tuberculous meningitis*
- While it can present with **lymphocytic pleocytosis**, tuberculous meningitis is characterized by **very low CSF glucose** (often <1.5 mmol/L) and **very high protein levels** (often >1-5 g/L).
- The clinical course is typically **subacute or chronic** (weeks to months), rather than the acute 24-hour presentation seen in this patient.
*Partially treated bacterial meningitis*
- This condition might show a shift towards **lymphocytic predominance** in the CSF, but the **glucose level** usually remains significantly low due to the initial bacterial consumption.
- There is no history provided in the clinical scenario to suggest the patient received **antibiotic treatment** prior to the lumbar puncture.
Question 144: A 58-year-old man with previously treated pulmonary tuberculosis develops recurrent disease. Culture and sensitivity testing reveals resistance to rifampicin and isoniazid, but sensitivity to ethambutol, pyrazinamide, and fluoroquinolones. What is the minimum recommended duration of treatment for his multidrug-resistant tuberculosis?
A. 6 months
B. 9 months
C. 12 months
D. 18 months (Correct Answer)
E. 24 months
Explanation: ***18 months***
- Multidrug-resistant tuberculosis (**MDR-TB**), defined by resistance to both **rifampicin and isoniazid**, requires a significantly prolonged treatment course compared to drug-sensitive TB.
- Global guidelines (e.g., WHO) typically recommend a minimum total duration of **18 to 20 months** for conventional, individualized regimens to ensure effective bacterial clearance and prevent relapse, often counted from the date of culture conversion.
*6 months*
- This duration is the standard for **drug-sensitive pulmonary TB** treated with the standard first-line regimen (RIPE).
- It is insufficient for **MDR-TB** because the core first-line drugs (rifampicin and isoniazid) are ineffective, leading to a high risk of treatment failure if used.
*9 months*
- A **9-month shorter regimen** exists for MDR-TB but is reserved for specific patient populations, particularly those without prior exposure to second-line drugs or resistance to **fluoroquinolones**.
- It is not the universal minimum recommended duration for all MDR-TB cases, especially those with a history of previous treatment.
*12 months*
- This duration is generally considered inadequate for standard **MDR-TB** management due to the slower bactericidal activity of second-line drugs and the high risk of **treatment failure** and relapse.
- While newer regimens are being explored, 12 months is not the established minimum for this patient profile.
*24 months*
- Treatment for **MDR-TB** can extend to **24 months** or longer in complex situations, such as **Extensively Drug-Resistant TB (XDR-TB)** or severe, extensive disease.
- However, it is not the *minimum* recommended duration for all MDR-TB; rather, it is reserved for the most challenging cases where prolonged therapy is deemed necessary.
Question 145: A 25-year-old man presents to the emergency department with a 10-hour history of fever, severe headache, and vomiting. On examination, he has a temperature of 39.2°C, heart rate 118/min, blood pressure 95/60 mmHg, and a non-blanching purpuric rash on his lower limbs. Which organism is most likely responsible for his clinical presentation?
A. Streptococcus pneumoniae
B. Neisseria meningitidis (Correct Answer)
C. Haemophilus influenzae
D. Listeria monocytogenes
E. Mycobacterium tuberculosis
Explanation: ***Neisseria meningitidis***- The presence of a **non-blanching purpuric rash** combined with fever, headache, and signs of **septic shock** (hypotension and tachycardia) is the hallmark presentation of **meningococcal septicaemia**.- This Gram-negative diplococcus is a leading cause of bacterial meningitis in **young adults** and requires immediate treatment with intravenous **ceftriaxone**.*Streptococcus pneumoniae*- While it is the most common cause of bacterial meningitis in adults, it typically presents without the characteristic **purpuric rash** seen in this patient.- It is more frequently associated with predisposing factors like **pneumonia**, **otitis media**, or **splenectomy**.*Haemophilus influenzae*- The incidence of meningitis caused by this organism has significantly decreased due to the widespread use of the **Hib vaccine**.- It usually affects **unvaccinated children** and lacks the rapidly progressive hemorrhagic rash characteristic of meningococcus.*Listeria monocytogenes*- This organism typically causes meningitis in specific high-risk groups, including the **elderly**, **pregnant women**, and the **immunocompromised**.- The clinical onset is often less hyperacute than meningococcal disease and is frequently associated with ingestion of **contaminated food**.*Mycobacterium tuberculosis*- Tuberculous meningitis generally follows a **subacute or chronic** course, with symptoms developing over weeks rather than hours.- Clinical findings usually include **basal meningitis**, cranial nerve palsies, and a more gradual decline in mental status compared to acute bacterial causes.
Question 146: A 34-year-old woman with pulmonary tuberculosis is currently on rifampicin, isoniazid, pyrazinamide, and ethambutol. She develops painful, red eyes with blurred vision. Ophthalmology examination reveals bilateral optic neuritis. Which medication is most likely responsible for this complication?
A. Rifampicin
B. Isoniazid
C. Pyrazinamide
D. Ethambutol (Correct Answer)
E. Streptomycin
Explanation: ***Ethambutol***- **Ethambutol** is classically associated with **dose-dependent optic neuritis**, leading to **decreased visual acuity**, **painful red eyes**, and **blurred vision**, often with **red-green color blindness**.- Patients on this drug must undergo baseline and periodic **ophthalmological screening** as the condition is usually reversible upon drug discontinuation.*Rifampicin*- Primary side effects include **hepatotoxicity** and a harmless **orange discoloration** of body fluids like urine, tears, and sweat.- It acts as a potent **cytochrome P450 inducer**, but it does not typically cause visual impairment or optic nerve damage.*Isoniazid*- Most commonly associated with **peripheral neuropathy** due to **pyridoxine (vitamin B6)** deficiency and potential hepatotoxicity.- While it can occasionally cause rare neurological issues, it is not the primary cause of sudden-onset **optic neuritis** in standard multidrug therapy.*Pyrazinamide*- The most frequent adverse effects are **hyperuricemia**, which may precipitate **gouty arthritis**, and hepatotoxicity.- It does not have any reported association with **ophthalmic toxicity** or blurred vision.*Streptomycin*- Known for its **ototoxicity**, which can lead to permanent hearing loss or **vestibular dysfunction** (vertigo and ataxia).- It is also associated with **nephrotoxicity** but does not cause the inflammatory changes in the optic nerve seen in this patient.
Question 147: A 36-year-old man from Bangladesh completes 6 months of treatment for drug-sensitive pulmonary tuberculosis with rifampicin, isoniazid, pyrazinamide, and ethambutol (2 months) followed by rifampicin and isoniazid (4 months). He is clinically well. End-of-treatment chest X-ray shows residual upper lobe fibrosis but no active disease. Sputum samples are smear and culture negative. He asks about risk of recurrence. Which factor most significantly increases his risk of TB relapse after treatment completion?
A. Presence of cavitation on initial chest X-ray
B. Country of origin with high TB prevalence
C. Residual radiological changes on chest X-ray
D. Positive sputum culture at 2 months of treatment (Correct Answer)
E. Duration of symptoms before diagnosis
Explanation: ***Positive sputum culture at 2 months of treatment*** - A **positive sputum culture** after the 2-month intensive phase is the most significant microbiological predictor of **TB relapse**, as it reflects a high persistent **bacillary load**. - Patients failing to achieve **culture conversion** by 2 months have a relapse risk significantly higher (approx. 5-10%) than those who convert early. *Presence of cavitation on initial chest X-ray* - While **cavitation** indicates a higher initial bacterial burden and is associated with delayed clearance, it is a baseline factor rather than a measure of treatment response. - It serves as an independent risk factor but is statistically less predictive of relapse than the **microbiological status** at the end of the intensive phase. *Country of origin with high TB prevalence* - Being from a high-prevalence area like **Bangladesh** increases the lifetime risk of **re-infection** with a new strain but does not necessarily increase the risk of **relapse** of the original strain. - Relapse is primarily determined by the efficacy of the treatment regimen and the patient's individual **immune response** to the initial infection. *Residual radiological changes on chest X-ray* - **Residual fibrosis** or scarring is a common sequela of healed pulmonary TB occurring in up to 50% of patients and does not imply the presence of **viable bacilli**. - As long as **sputum cultures** are negative at the end of treatment, these stable radiographic findings do not increase the risk of the disease returning. *Duration of symptoms before diagnosis* - A longer duration of symptoms before starting therapy may correlate with more extensive **lung tissue damage**, but it is not a direct predictor of treatment failure. - The **rate of clearance** of the organism during the first 8 weeks of therapy is a much more robust indicator of long-term cure than the pre-treatment symptom duration.
Question 148: A 51-year-old man from Zimbabwe with newly diagnosed HIV (CD4 count 45 cells/mm³, viral load 450,000 copies/mL) presents with a 4-week history of headache, confusion, and fever. Cryptococcal antigen (CrAg) in serum and CSF is positive. Opening pressure on LP is 38 cmH2O. He is started on liposomal amphotericin B and flucytosine. When is the most appropriate time to initiate antiretroviral therapy?
A. Immediately, alongside antifungal therapy
B. After 2 weeks of antifungal therapy
C. After 4-6 weeks of antifungal therapy (Correct Answer)
D. After completion of induction therapy (2 weeks) and consolidation therapy (8 weeks)
E. Only after CSF cryptococcal antigen becomes negative
Explanation: ***After 4-6 weeks of antifungal therapy***- Guidelines recommend deferring **antiretroviral therapy (ART)** for 4-6 weeks in patients with **cryptococcal meningitis** to reduce the risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)**.- Clinical trials (like the **COAT trial**) demonstrated that earlier initiation of ART is associated with a significantly **higher mortality** rate due to intracranial complications associated with IRIS.*Immediately, alongside antifungal therapy*- Starting ART immediately is contraindicated because it poses an extremely high risk of **IRIS**, which can lead to fatal brain swelling and **raised intracranial pressure**.- This approach is typically only reserved for other opportunistic infections like **Pneumocystis pneumonia (PCP)** or toxoplasmosis, but not for fungal meningitis.*After 2 weeks of antifungal therapy*- While 2 weeks marks the end of the **induction phase**, studies show that initiating ART at this point still carries an unacceptably high risk of lethal **meningeal inflammation**.- Delaying further allows the **fungal burden** to decrease significantly before the immune system begins its recovery.*After completion of induction therapy (2 weeks) and consolidation therapy (8 weeks)*- Waiting a total of 10 weeks is unnecessarily long and increases the risk of other **AIDS-defining illnesses** or death due to profound immunosuppression.- The optimal balance to prevent both **IRIS** and opportunistic infections is achieved by starting ART between the **4th and 6th week**.*Only after CSF cryptococcal antigen becomes negative*- **Cryptococcal antigen (CrAg)** in the CSF can remain positive for months or years, even with successful treatment, and is not a marker for timing ART.- Treatment success is monitored via **CSF culture negativity** rather than the clearance of the polysaccharide antigen itself.
Question 149: A 29-year-old woman presents with headache, fever, and photophobia. LP shows: opening pressure 24 cmH2O, CSF clear with 450 white cells/mm³ (85% lymphocytes), protein 0.8 g/L, glucose 3.2 mmol/L (plasma glucose 5.8 mmol/L). She was treated with IV aciclovir for suspected HSV encephalitis. CSF PCR is negative for HSV, VZV, and enteroviruses. Blood and CSF cultures are sterile at 48 hours. She improves clinically. What is the most likely diagnosis?
A. Partially treated bacterial meningitis
B. Tuberculous meningitis
C. Viral meningitis with false-negative PCR (Correct Answer)
D. Fungal meningitis
E. Neurosarcoidosis
Explanation: ***Viral meningitis with false-negative PCR***\n - The CSF profile shows **lymphocytic pleocytosis**, mildly elevated protein, and a **normal glucose ratio** (>0.5), which is classic for a viral etiology.\n - While **PCR** is highly sensitive for HSV, VZV, and enteroviruses, it can be **falsely negative** depending on the timing of the lumbar puncture or the specific viral agent involved; spontaneous clinical improvement further supports this diagnosis.\n*Partially treated bacterial meningitis*\n - This typically presents with a **neutrophilic predominance** initially and a significant **drop in CSF glucose**, which are not seen here.\n - The patient improved clinically without receiving **antibiotics**, making a bacterial cause highly unlikely.\n*Tuberculous meningitis*\n - Tuberculous meningitis usually presents with a very high protein level and **markedly low glucose** (less than 50% of plasma glucose).\n - The clinical course of TB meningitis is typically **subacute or chronic** and does not resolve rapidly without specific anti-tubercular therapy.\n*Fungal meningitis*\n - Often caused by **Cryptococcus**, it is primarily seen in **immunocompromised patients** and usually features low glucose levels.\n - Fungal infections follow an **indolent course** rather than the acute presentation and rapid improvement described in this case.\n*Neurosarcoidosis*\n - This is a rare **granulomatous disease** that usually presents with cranial nerve palsies or chronic symptoms rather than acute fever and photophobia.\n - While it can cause **lymphocytic pleocytosis**, it would not typically show sudden clinical improvement without **steroid treatment**.
Question 150: A 44-year-old woman with rheumatoid arthritis on methotrexate and newly commenced tocilizumab (IL-6 inhibitor) undergoes screening for latent tuberculosis. Mantoux test shows 18 mm induration at 48 hours. Chest X-ray shows calcified granuloma in the right upper zone but no active disease. Interferon-gamma release assay is positive. She has no symptoms of active TB. What is the most appropriate management?
A. Commence isoniazid monotherapy for 6 months; continue tocilizumab
B. Commence rifampicin and isoniazid for 3 months; defer tocilizumab until completed (Correct Answer)
C. No treatment required; continue tocilizumab with regular monitoring
D. Commence rifampicin monotherapy for 4 months; defer tocilizumab for 2 months
E. Treat as active tuberculosis with four-drug therapy; discontinue tocilizumab
Explanation: ***Commence rifampicin and isoniazid for 3 months; defer tocilizumab until completed***- The patient presents with **latent tuberculosis infection (LTBI)**, confirmed by a positive **Mantoux test** (18mm induration), positive **IGRA**, and a **calcified granuloma** on Chest X-ray, all in the absence of active symptoms. This necessitates treatment before immunosuppressive biologics.- A 3-month course of **rifampicin and isoniazid** is a standard and effective regimen for LTBI, particularly beneficial for patients starting **biologic therapy** (like tocilizumab) where deferring the biologic until treatment completion is crucial to prevent **reactivation**.*Commence isoniazid monotherapy for 6 months; continue tocilizumab*- While **isoniazid monotherapy** for 6-9 months is a valid treatment for LTBI, continuing **tocilizumab** (an IL-6 inhibitor) concurrently significantly increases the risk of **TB reactivation** before the prophylactic treatment has had time to be fully effective.- Biologic agents should generally be withheld or deferred until the completion of LTBI treatment or at least until a substantial portion of the treatment (e.g., 1-2 months) has been completed, to ensure adequate protection.*No treatment required; continue tocilizumab with regular monitoring*- This approach is incorrect as the patient has clear evidence of **latent tuberculosis infection** (positive Mantoux, positive IGRA, calcified granuloma) and is on powerful **immunosuppressive therapy** (tocilizumab).- Continuing tocilizumab without treating LTBI would significantly increase her risk of developing **active tuberculosis**, which can be severe and life-threatening in immunocompromised individuals.*Commence rifampicin monotherapy for 4 months; defer tocilizumab for 2 months*- **Rifampicin monotherapy** for 4 months is an acceptable alternative regimen for LTBI, offering a shorter duration than isoniazid monotherapy.- However, deferring tocilizumab for only **2 months** while on a 4-month regimen may still leave the patient vulnerable to reactivation during the remaining treatment period or shortly after re-initiation of the biologic; completing the full LTBI treatment before re-starting the biologic is generally safer.*Treat as active tuberculosis with four-drug therapy; discontinue tocilizumab*- This patient does not have **active tuberculosis**; the chest X-ray shows only a **calcified granuloma** and she is asymptomatic. Four-drug therapy (e.g., RIPE: rifampicin, isoniazid, pyrazinamide, ethambutol) is indicated only for active disease.- Treating LTBI with an aggressive four-drug regimen meant for active TB is excessive and carries a higher risk of **drug toxicity** (especially hepatotoxicity) without additional benefit for latent disease.
